Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...